Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP26A1 | O43174 | 1/20 | 0.47 |
| ▸ | CTSL | P07711 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | CRHBP | P24387 | 1/20 | 0.44 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.42 |
| ▸ | BCHE | P06276 | 2/20 | 0.42 |
| ▸ | ACHE | P22303 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10131060 | 0.95 | CYP26A1 (0.51) | CYP26A1CTSLSMN1; SMN2RAB9AGAA | |
| SCHEMBL12020054 | 0.91 | CYP26A1 (0.48) | CYP26A1CTSLSMN1; SMN2RAB9AGAA | |
| SCHEMBL12019153 | 0.89 | ALDH1A1 (0.51) | CTSLRAB9AMEN1KMT2AALDH1A1 | |
| SCHEMBL30843763 | 0.83 | GAA (0.53) | CYP26A1CTSLRAB9AGAAKMT2A | |
| SCHEMBL2673046 | 0.83 | CYP26A1 (0.48) | CYP26A1CTSLSMN1; SMN2RAB9AGAA | |
| SCHEMBL28338111 | 0.83 | CYP26A1 (0.48) | CYP26A1CTSLSMN1; SMN2RAB9AGAA | |
| SCHEMBL14671278 | 0.82 | GAA (0.47) | CYP26A1CTSLRAB9AGAAP2RY12 | |
| SCHEMBL29188972 | 0.82 | CYP26A1 (0.54) | CYP26A1CTSLSMN1; SMN2RAB9AGAA | |
| SCHEMBL3692412 | 0.82 | RAB9A (0.48) | CYP26A1CTSLSMN1; SMN2RAB9AGAA | |
| SCHEMBL7610226 | 0.82 | RAB9A (0.48) | CYP26A1CTSLSMN1; SMN2RAB9AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8962692-B2 | Cysteine and cystine prodrugs to treat schizophrenia and reduce drug cravings | MARQUETTE UNIVERSITY (US) | 2015-02-24 | — | — | US | disclosed |
| US-20120220596-A1 | CYSTEINE AND CYSTINE PRODRUGS TO TREAT SCHIZOPHRENIA AND REDUCE DRUG CRAVINGS | UWM RESEARCH FOUNDATION, INC. (US) | 2012-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220596-A1 | CYSTEINE AND CYSTINE PRODRUGS TO TREAT SCHIZOPHRENIA AND REDUCE DRUG CRAVINGS | CTH, SLC7A11, CBS | CYP26A1 960/4885CTSL 544/4885SMN1; SMN2 4736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.